ERBB2 and breast carcinoma: The positive therapeutic effect of afatinib in the treatment of breast cancer, in particular trastuzumab‐resistant HER2‐positive breast cancer, has been observed in phase I/II clinical studies (Canonici et al., 2016; Hurvitz et al., 2014; Lin et al., 2012).